Provided by Tiger Trade Technology Pte. Ltd.

CALIDI BIOTHERAPEUTICS INC

1.31
-0.0500-3.68%
Post-market: 1.27-0.0400-3.05%19:52 EDT
Volume:32.40K
Turnover:42.80K
Market Cap:3.39M
PE:-0.04
High:1.34
Open:1.31
Low:1.30
Close:1.36
52wk High:27.84
52wk Low:1.25
Shares:2.58M
Float Shares:2.56M
Volume Ratio:1.03
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-33.3374
EPS(LYR):-95.1334
ROE:-672.22%
ROA:-134.79%
PB:1.08
PE(LYR):-0.01

Loading ...

Calidi Biotherapeutics to Participate in H.C. Wainwright Annual Global Investment Conference

Reuters
·
Sep 08

Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY

Benzinga Earnings
·
Aug 14

Calidi Biotherapeutics Q2 FY26 Net Loss Narrows 26.32% to $4.2 Million; General and Administrative Expense Drops 48% to $1.6 Million

Reuters
·
Aug 14

Calidi Biotherapeutics - Reports Q2 Net Loss of $4.20 Mln, or $2.94 Per Share

THOMSON REUTERS
·
Aug 14

Press Release: Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Dow Jones
·
Aug 14

Calidi Biotherapeutics Effects 1-for-16 Reverse Stock Split

Reuters
·
Aug 01

Calidi Biotherapeutics Targets Q1 2027 Clinic Entry for Cld-401 Cancer Program

Reuters
·
Jul 27

Calidi Biotherapeutics Provides Mid-year Corporate Update and Future Key Value Drivers

THOMSON REUTERS
·
Jul 21

Calidi Biotherapeutics - Reduces G&a Expenses by $1 Mln from Q1 2025 to Q1 2026

THOMSON REUTERS
·
Jul 21

Calidi Biotherapeutics - Targets First Patient Dosing in Cld-401 Phase I Trial in Q1 2027

THOMSON REUTERS
·
Jul 21

Calidi Biotherapeutics Announces 1-for-16 Reverse Stock Split Effective July 31

Reuters
·
Jul 21

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

THOMSON REUTERS
·
Jul 21

Calidi Biotherapeutics Grants VP Finance Inducement Option for 100,000 Shares at $0.15 Exercise Price

Reuters
·
Jul 09

Calidi Biotherapeutics Director Corazon “corsee” Sanders Files Initial Beneficial Ownership Statement

Reuters
·
Jun 30

Calidi Biotherapeutics Presents New Preclinical Data on Trop2-targeting Cld-501 at T-cell Engager Summit

Reuters
·
Jun 24

Calidi Biotherapeutics appoints former Genentech, Celgene executive Corsee Sanders to board

Reuters
·
Jun 23

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.d., to Board of Directors

THOMSON REUTERS
·
Jun 23

Calidi Biotherapeutics shareholders approve reverse stock split authorization

Reuters
·
Jun 19

Calidi receives pre-IND regulatory feedback from FDA for CLD-401

TIPRANKS
·
Jun 16

Calidi Biotherapeutics targets early 2027 start for first-in-human CLD-401 trial after FDA pre-IND feedback

Reuters
·
Jun 16